- United States
- Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLIin Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLIin Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
- X (Twitter)
Copy link